OrigAMI-4 study shows strong tumor responses in patients with recurrent or metastatic head and neck cancer after standard treatments fail. Johnson & Johnson has announced promising clinical results for its investigational therapy RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in patients with advanced head and neck squamous cell carcinoma (HNSCC), a disease where treatment options remain limited once standard therapies stop working.

Atherosclerosis, the gradual buildup of fatty deposits inside arteries, remains one of the leading causes of heart attacks and strokes worldwide. While inflammation has long been recognized as a major contributor to the disease, new research from scientists at Ludwig Maximilian University of Munich suggests that certain inflammatory immune cells may also play a protective role in slowing its progression.